|
Diabetes Medication Article
Types of Insulin Delivery Devices
All insulin delivery devices inject insulin through the skin and into
the fatty tissue below.
Most people inject the insulin with a syringe that delivers insulin just
under the skin. Others use insulin pens, jet injectors, or insulin pumps.
Several new approaches for taking insulin are under development.
Insulin Delivery Devices Under Development
Researchers are now developing several new methods for delivering insulin. These include the insulin patch and inhaled insulin. The insulin patch, when placed on the skin, will give a continuous, low dose of insulin. To adjust insulin doses before meals, users will pull off the tab on the patch to release insulin. Inhaled insulin delivery systems will give insulin as a dry power, inhaled through the mouth directly into the lungs where it passes into the bloodstream. This aerosol delivery system will likely be about the size of a flashlight and use rapid-acting insulin.
Diabetes Testing Center
Heart News Center
Hot Home Gym Reviews
The Secret Wisdom You Have Inside
Get Rid of Your Belly fat
Actos Drug News
Actos Drug
IMPORTANT: Bing News RSS feed has moved!
The US Drug Watchdog is now calling its initiative focused on the diabetes drug called Actos, and diabetics who used this drug, and then developed bladder cancer, one of its important initiatives ever. They say, "We want to identify every user of the ...
Read moreUS Drug Watchdog Now Calls Its Initiative for Diabetics Who Used the Diabetes Drug Actos and Then De
Dec. 30 (Bloomberg) -- Lawsuits against Takeda Pharmaceutical Co., Asia’s biggest drugmaker, claiming its Actos diabetes drug causes bladder cancer will be consolidated before one judge in federal court in Louisiana, a judicial panel said.
Read moreTakeda Actos Suits Combined in Louisiana Court, Panel Rules
Lawsuits against Takeda Pharmaceutical Co. (4502), Asia’s biggest drugmaker, claiming its Actos diabetes drug causes bladder cancer will be consolidated before one judge in federal court in Louisiana, a judicial panel said. The federal ...
Read moreTakeda Actos Cancer Suits Combined in Louisiana Court, U.S. Panel Rules
The Actos lawsuits claim that the drug causes bladder cancer, a side effect about which the manufacturer and co-defendant Eli Lilly & Co. failed to properly warn the public. In September, Takeda reported that 54 federal Actos lawsuits had been ...
Read moreActos Lawsuits to be Consolidated in Louisiana Court
In 2010, Type 2 diabetes drug Actos generated approximately $4.8 billion in revenues for its manufacturer, Takeda Pharmaceuticals. According to a recent report from Bloomberg, the company will most likely see a loss of up to $2.1 billion in Actos sales in ...
Read moreActos Sales Predicted to Falter as Takeda Faces More Lawsuits
Included in the California consolidated cases are three Actos lawsuits brought by the national law firm of Baum, Hedlund, Aristei & Goldman, alleging that the diabetes medication caused bladder cancer in their clients, and that Japan-based Actos ...
Read moreActos Plaintiffs Attorneys Vow to Keep California Bladder Cancer Cases in State Court
The United States Judicial Panel on Multidistrict Litigation Announces Actos MDL. Multidistrict litigation (MDL) is used when civil actions in more than one court involve one or more common questions of fact. An MDL is then established to efficiently guide ...
Read moreThe Texas Actos Attorneys at Grossman Law Offices Continue to Provide Victims with Up-To-Date Information about Their Drug Injury Lawsuit
Important 2012 US generic launches for Mylan include Provigil, Diovan, Zyprexa, Plavix, Actos/Actoplus, Viramune, Clarinex, Singulair and Avapro. Teva, another force in the generic space, has drugs like Avandia, Avandamet, and Avandaryl, Actos/Actoplus and ...
Read moreRing in Generics in 2012 and Beyond
Takeda Pharmaceutical Company Ltd (TKPYY.PK)'s type 2 diabetes medication Actos, and Amgen Inc. (AMGN)'s arthritis and psoriasis treatment Enbrel. Shares of other hepatitis C drug developers rallied on the Inhibitex deal. Seen as potential take ...
Read more